Cellid, Co., Ltd. (KOSDAQ:299660)
South Korea · Delayed Price · Currency is KRW 1,920.00
+237.00 (14.08%)
Aug 11, 2026, 3:30 PM KST
Cellid, Market Cap
Cellid, has a market cap or net worth of 56.65 billion as of August 11, 2026. Its market cap has decreased by -54.77% in one year.
Market Cap
56.65B
Enterprise Value
n/a
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
1,920.00
ChartMarket Cap Chart
Since February 20, 2019, Cellid,'s market cap has decreased from 482.44B to 56.65B, a decrease of -88.26%. That is a compound annual growth rate of -24.91%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 11, 2026 | 56.65B | -32.87% |
| Dec 30, 2025 | 84.38B | -20.98% |
| Dec 30, 2024 | 106.78B | 75.61% |
| Dec 28, 2023 | 60.81B | -46.82% |
| Dec 29, 2022 | 114.34B | -76.07% |
| Dec 30, 2021 | 477.80B | 21.04% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Feb 20, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Samsung Biologics | 72.63T |
| Celltrion | 46.09T |
| ALTEOGEN | 24.23T |
| Samsung Epis Holdings | 10.48T |
| Humasis | 55.56B |
| Oncocross | 51.79B |
| EOFLOW | 51.11B |
| Aprogen Biologics | 49.90B |